PT  - JOURNAL ARTICLE
AU  - Hoogwerf, Byrom J.
AU  - Young, James B.
TI  - The Hope Study
DP  - 2000 Apr 01
TA  - Cleveland Clinic Journal of Medicine
PG  - 287--293
VI  - 67
IP  - 4
4099  - http://www.ccjm.org/content/67/4/287.short
4100  - http://www.ccjm.org/content/67/4/287.full
SO  - Cleve Clin J Med2000 Apr 01; 67
AB  - The Heart Outcomes Prevention Evaluation (HOPE) study found that the ACE inhibitor ramipril can lower the risk of atherosclerotic disease events and death in patients without heart failure but with known atherosclerosis or with diabetes plus at least one cardiovascular risk factor. This benefit was independent of ramipril’s effect on blood pressure. Additional benefits were a reduced risk of diabetic nephropathy in diabetic patients, and a lower likelihood of newly diagnosed diabetes. On the other hand, vitamin E in the doses and duration studied (400 IU/day for 4.5 years) did not lower risk significantly.